# Ensysce Biosciences (ENSC) — Earnings

ENSC · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/ensc/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | −$0.79 |
| EPS estimate | −$1.02 |
| EPS surprise | +22.17% |
| Revenue surprise | +0.00% |
| Revenue | $0.00 |
| Revenue estimate | $650,000.00 |
| Reported | Aug 13, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1716947/000164117225023512/form10-q.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 13, 2025 | −$1.02 | −$0.79 | 22.17% | $650,000.00 | — |
| Q1 2025 | May 13, 2025 | −$3.02 | −$1.39 | 53.90% | — | $1.3M |
| Q4 2024 | Mar 10, 2025 | −$2.74 | −$2.90 | -6.03% | $245,000.00 | $1.3M |
| Q3 2024 | Nov 12, 2024 | $1.05 | $1.05 | 0.00% | $3.4M | $3.4M |
| Q2 2024 | Aug 14, 2024 | −$5.85 | −$3.30 | 43.59% | $300,000.00 | $200,000.00 |
| Q1 2024 | May 13, 2024 | −$13.50 | −$8.25 | 38.89% | $400,000.00 | $305,000.00 |
| Q4 2023 | Mar 15, 2024 | −$13.05 | −$16.95 | -29.89% | $395,000.00 | $505,000.00 |
| Q3 2023 | Nov 9, 2023 | −$15.85 | −$13.05 | 17.67% | $593,333.00 | $420,000.00 |
| Q2 2023 | Aug 11, 2023 | −$27.80 | −$14.70 | 47.12% | $760,000.00 | $495,000.00 |
| Q1 2023 | May 15, 2023 | −$76.15 | −$31.20 | 59.03% | $950,000.00 | $800,000.00 |
| Q3 2022 | Nov 14, 2022 | −$28.80 | −$923.40 | -3106.25% | $1.0M | $300,000.00 |
| Q2 2022 | Aug 11, 2022 | −$30.60 | −$43.20 | -41.18% | $1.0M | $200,000.00 |
| Q1 2022 | May 12, 2022 | −$28.80 | −$10.80 | 62.50% | $1.2M | $600,000.00 |
| Q4 2021 | Mar 31, 2022 | $16.20 | −$81.00 | -600.00% | $800,000.00 | $1.0M |
| Q3 2021 | Nov 15, 2021 | −$127.80 | −$127.80 | 0.00% | $1.2M | $1.2M |
| Q2 2021 | Aug 16, 2021 | $0.00 | −$10.80 | 0.00% | — | $400,000.00 |

## Frequently Asked Questions

### When did Ensysce Biosciences (ENSC) last report earnings?

Ensysce Biosciences last reported on Aug 13, 2025, covering fiscal Q2 2025.

### Did ENSC beat earnings estimates?

Yes. Ensysce Biosciences reported EPS of −$0.79 for Q2 2025 against a −$1.02 estimate — a 22.17% beat.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).